Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience powered by Apple
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions powered by Apple

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Blog
Checkpoint Frenzy
How innovations in the checkpoint inhibitor space are causing a glut in the global clinical research landscape
Jeff Hodge, Vice President, Medical Strategy Lead, Oncology Center of Excellence
Apr 11, 2022
  • Blogs
  • Checkpoint Frenzy

Checkpoint inhibitors have transformed the oncology landscape, bringing new hope to cancer patients across globe. Checkpoint inhibitors, which allow the immune system to attack cancer tumors, have been the catalyst for many recent clinical advances and overall development of immuno-oncology (IO) therapies.

But their extraordinary impact has also crowded the research environment with more trials than there may be patients to serve. As the PD-1/PD-L1 treatment modality continues to play a major role in IO, it is drawing a flood of new competitors into the research landscape.

A decade later

The US Food and Drug Administration (FDA) approved the first checkpoint inhibitor anti-CTLA4 to treat melanoma in 2012. Since then, they have become the backbone of the oncology treatment space, displacing chemotherapy for many indications.

While the response rate varies among populations, for those patients who do respond to these treatments, responses are durable with prolonged progression free survival and overall survial compared to chemotherapy. These findings have propelled checkpoint inhibitors from salvage therapy in the metastatic setting to front line treatments and into the neoadjuvant and adjuvant settings in many tumor types.

The progress has been amazing, especially given the short amount of time these treatments have been in the marketpace.

In the decade since the first approval, FDA has approved seven more PD-1/PD-L1 inhibitors; four anti-PD1s; and three anti-PD-L1 monoclonal antibodies (mAbs), including the recent accelerated approval of the anti-PD1 mAb, Dostarlimab, in April 2021.

These therapies are having a profound effect on patients’ lives, and generating significant revenue streams for their developers. The average treatment cost can exceed $150,000, while combination therapies can exceed $300,000 for some treatment options.

Within five years of the first approval, the checkpoint inhibitors marketplace exceeded $10.56 billion in annual revenues. By 2025, it is expected to reach $30 billion, with a CAGR of more than 20% per year. Much of this growth will come from emerging markets, where demand for innovative cancer treatments is growing.

Currently much of the excitement is about combination therapies and new formulations. Roughly 83% of the anti-PD1/L1 active studies are testing combination regimens, including IO therapies, targeted therapies, chemotherapies and radiotherapies. And more than a dozen PD-1/PD-L1 inhibitors are now being developed for oral delivery. This could be a significant gamechanger for patients, who can take these treatments at home rather than sitting for hours at a clinic getting an IV infusion.

Too much of a good thing?

All of this success is creating a frenzy in the research space, as developers race to bring the next best checkpoint inhibitor, or combination therapy to market. As of December 2021, IQVIA data shows that there are more than 4,897 clinical trials testing anti-PD1/L1 mAbs, 4,062 of which are currently active. This represents a 267% increase in the total number of clinical trials since 2017.

While innovation is essential to improve anti-PD-1/PD-L1 therapies, the volume of clinical trials, either novel combinations or “me-too” PD-1/PD-L1s, in this space has introduced challenges in finding patients who have not been previously exposed to checkpoint inhibitors. And many trials are testing immunotherapies that offer only nominal improvements over what is currently in the marketplace, so there are challenges generating clinician or patient enthusiasm for taking part.

The FDA’s top oncologists, Rick Pazdur and Julia Beaver have commented recently on the development landscape with these therapies. “Efforts to corral this enthusiasm should focus on increased international partnerships between sponsors of approved checkpoint inhibitors and those developing novel agents to be used with anti–PD-1 and anti–PD-L1 antibodies rather than developing ‘me too’ drugs,” Beaver and Pazdur wrote in the New England Journal of Medicine in December 2021.

They lamented the fact that the current landscape includes many companies hoping to take a familiar, albeit shorter path to accelerated approval (45% of indications in this class of PDL1s have taken the accelerated route), often via single-arm trials, and as confirmatory randomized clinical trials “designed to verify their benefits have shown inconsistent results.”

The FDA “now cautions sponsors developing checkpoint inhibitors against pursuing single-arm trials in patients with refractory disease for the purpose of drug approval,” Pazdur and Beaver wrote.

Sponsors seeking to claim they’re developing “a better” checkpoint inhibitor “should directly compare their agent with those that are already approved; unfortunately, there is no evidence that such randomized trials are under way,” they added.

For further discussion of trends in the PD-1/PD-L1 inhibitor space, please see recent publications by IQVIA experts, including this February 2022 article on Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape; and this 2020 piece on the rise in combination therapies for PD1/PDL1 inhibitor trials.

For more information about IQVIA’s oncology clinical research services,
please visit https://www.iqvia.com/solutions/therapeutics/oncology. 

Related solutions

Oncology

Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.

Therapeutic & Specialty Expertise

Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.

Contact Us